These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 16257369

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
    Takimoto CH.
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
    [Abstract] [Full Text] [Related]

  • 12. Private development companies: transforming academic research into new treatment options for cancer.
    Janoff AS.
    Mol Interv; 2010 Apr; 10(2):65-8. PubMed ID: 20368364
    [No Abstract] [Full Text] [Related]

  • 13. Portfolio analysis and R&D decision making.
    Evans R, Hinds S, Hammock D.
    Nat Rev Drug Discov; 2009 Mar; 8(3):189-90. PubMed ID: 19182818
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Sir David Weatherall reflects on genetics and personalized medicine. Interviewed by Ulrike Knies-Bamforth.
    Weatherall D.
    Drug Discov Today; 2006 Jul; 11(13-14):576-9. PubMed ID: 16862731
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Clinical setbacks for toll-like receptor 9 agonists in cancer.
    Schmidt C.
    Nat Biotechnol; 2007 Aug; 25(8):825-6. PubMed ID: 17687345
    [No Abstract] [Full Text] [Related]

  • 18. Developing an oncology portfolio of anticancer drugs: the experience of one pharmaceutical company.
    Blackledge GR.
    Zentralbl Gynakol; 2005 Dec; 127(6):385-8. PubMed ID: 16341982
    [Abstract] [Full Text] [Related]

  • 19. Amgen becomes a stronger cancer player.
    Kling J.
    Nat Biotechnol; 2006 Feb; 24(2):119. PubMed ID: 16465140
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.